09:47 AM EST, 12/09/2024 (MT Newswires) -- Stereotaxis ( STXS ) said Monday its Magbot Magnetic Navigation Ablation Catheter, developed with Shanghai MicroPort EP Medtech, received regulatory approval from China's National Medical Products Administration.

The company said the Magbot catheter, used for treating specific heart rhythm disorders, is designed for use with Stereotaxis' ( STXS ) robotic systems and MicroPort's mapping technology.

The device enables robotically controlled ablation procedures, supporting access and accuracy in cardiac treatments, Stereotaxis ( STXS ) said.

MicroPort EP plans to market the device in China, with Stereotaxis ( STXS ) sharing in revenue generated from sales, the company added.

Price: 2.26, Change: +0.05, Percent Change: +2.26